Vivo Capital Takes Dutscher Group From LBO France in European Lab Supplies Exit

Vivo Capital, the Palo Alto-based life sciences investor with $8.2 billion under management, acquired Dutscher Group from LBO France in a transaction announced January 14. Terms were not disclosed. The deal marks a secondary exit for LBO France, which backed the Brumath, France-based laboratory supplies distributor in 2021.

Dutscher Group operates across nine European countries with 15 distribution centers, serving research laboratories, universities, and pharmaceutical manufacturers. The company stocks approximately 850,000 SKUs ranging from pipettes to mass spectrometry consumables. Revenue for the twelve months ending December 2024 reached approximately €420 million, according to market sources familiar with the business. LBO France's entry valuation in 2021 was reported at 11.2x EBITDA on a €32 million trailing basis. Current EBITDA margins sit near 9%, below the 12-14% range typical for scaled lab distribution but reflecting investments in digital ordering infrastructure completed during LBO France's ownership.

The transaction puts a US life sciences specialist into a European fragmented market where consolidation has accelerated since 2022. Dutscher competes directly with VWR International (now part of Avantor), Fisher Scientific's European division, and regional players like Th. Geyer and Carl Roth. Vivo Capital's European portfolio already includes diagnostics manufacturer Diagenode and bioprocessing equipment provider Univercells. The firm typically holds investments for six to eight years, suggesting Dutscher may serve as a platform for bolt-on acquisitions across Central and Southern Europe. Independent distributors in Spain, Italy, and Poland with €15-60 million in revenue trade at 8-10x EBITDA and lack the warehouse automation Dutscher installed in 2023.

LBO France's exit comes 39 months after entry, shorter than the fund's historical 52-month median hold. The firm raised its sixth fund at €620 million in November 2024 and typically targets French mid-market businesses with €200-500 million enterprise values. Dutscher represented a smaller check within that mandate. French PE exits reached €18.3 billion in 2024, down 23% from 2023, according to France Invest. Secondary sales to US buyers accounted for 41% of French PE exits last year, up from 29% in 2022, reflecting European firms' preference for dollar-denominated liquidity.

Allocators should monitor Vivo Capital's acquisition pace in European lab infrastructure over the next 18 months. The firm's Fund VIII, a $2.1 billion vehicle closed in 2023, remains 67% undeployed. European life sciences M&A multiples have compressed 180 basis points since mid-2023 as interest rates stabilized, creating entry opportunities for funds with dry powder. Watch whether Dutscher pursues acquisitions in Iberia or the Nordics, regions where local distributors lack national scale. Also watch LBO France's deployment from its new fund—the firm typically announces two to three platform investments within 12 months of a fund close.

Dutscher's logistics footprint now gives Vivo Capital access to pharmaceutical supply chains across France, Germany, Belgium, and the Netherlands, four of Europe's five largest research budgets.